References
- Nakashima T, Naganawa S, Sugiura M, Teranishi M, Sone M, Hayashi H, et al. Visualization of endolymphatic hydrops in patients with Meniere's disease. Laryngoscope 2007;117:415–20.
- Yamazaki M, Naganawa S, Kawai H, Sone M, Nakashima T. Gadolinium distribution in cochlear perilymph: differences between intratympanic and intravenous gadolinium injection. Neuroradiology 2012;54:1161–9.
- Tsushima Y, Takahashi-Taketomi A, Endo K. Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible. Radiology 2008;247:915–6.
- Kimitsuki T, Nakagawa T, Hisashi K, Komune S, Komiyama S. Gadolinium blocks mechano-electric transducer current in chick cochlear hair cells. Hear Res 1999;101:75–80.
- Tanigawa T, Tanaka H, Banno S, Inafuku S. In reference to visualization of endolymphatic hydrops in patients with Meniere's disease. Laryngoscope 2008;118:946.
- Runge VM, Ai T, Hao D, Hu X. The developmental history of the gadolinium chelates as intravenous contrast media for magnetic resonance. Invest Radiol 2011;46:807–16.
- Nakashima T, Naganawa S, Katayama N, Teranishi M, Nakata S, Sugiura M, et al. Clinical significance of endolymphatic imaging after intratympanic gadolinium injection. Acta Otolaryngol Suppl 2009;560:9–14.
- Daniel SJ, Duval M, Sahmkow S, Akache F. Ototoxicity of topical moxifloxacin in a chinchilla animal model. Laryngoscope 2007;117:2201–5.
- Russell PT, Church CA, Jinn TH, Kim DJ, John EO, Jung TT. Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells. Acta Otolaryngol 2001;121:135–9.
- Tanigawa T, Tanaka H, Hayashi K, Nakayama M, Iwasaki S, Banno S, et al. Effects of hydrogen peroxide on vestibular hair cells in the guinea pig: importance of cell membrane impairment preceding cell death. Acta Otolaryngol 2008;128:1196–202.
- Food and Drug Administration. 2006;Public health advisory: gadolinium containing contrast agents for magnetic resonance imaging (MRI): Omniscan, OptiMARK, Magnecist, Pro-Hance, and MultiHance. Rockville, MD: FDA.
- High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21–6.
- Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008;66:230–4.
- Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008;3:747–51.
- Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27:S2–6.
- White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272–8.
- Tanaka H, Tanigawa T, Suzuki M, Otsuka K, Inafuku S. Effects of MRI contrast agents (Omniscan) on vestibular end organs. Acta Otolaryngol 2010;130:17–24.
- Greisberg JK, Wolf JM, Wyman J, Zou L, Terek RM. Gadolinium inhibits thymidine incorporation and induces apoptosis in chondrocytes. J Orthop Res 2001;19:797–801.
- Ray DE, Holton JL, Nolan CC, Cavanagh JB, Harpur ES. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. Am J Neuroradiol 1998;19:1455–62.
- Morizono T. Safety of antimicrobial applied in the middle ear cavity. Pract Otol (Kyoto) 2002;95:663–9.